Travere Therapeutics Q4 Earnings Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy TVTX?
Source: seekingalpha
- Earnings Report: Travere Therapeutics reported a Q4 non-GAAP EPS of $0.37, aligning with market expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q4 revenue of $129.69 million, a 73.4% year-over-year increase, although it missed expectations by $17.99 million, reflecting intensified market competition and sales challenges.
- Filspari Progress: The FDA's delay in reviewing Filspari for a rare kidney disorder presents challenges, yet market expectations for its approval remain high, potentially impacting future sales growth.
- Market Outlook: Looking ahead to 2026, Travere Therapeutics anticipates that Filspari's market potential will continue to drive company growth, despite the short-term impact of the FDA review delay.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 29.790
Low
31.00
Averages
42.89
High
49.00
Current: 29.790
Low
31.00
Averages
42.89
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Travere Therapeutics Q4 2025 Earnings Call Highlights
- Record Sales Performance: Travere Therapeutics achieved U.S. net product sales of $103 million for FILSPARI in Q4 2025, with total sales reaching $322 million for the year, reflecting a remarkable 144% year-over-year growth that underscores strong market demand and physician confidence, solidifying the company's leadership in IgA nephropathy treatment.
- Significant Clinical Progress: Management confirmed the acceptance of the supplemental NDA for FILSPARI in FSGS, with a revised PDUFA date of April 13, 2026, which is expected to open new market opportunities and further propel FILSPARI's clinical application and commercialization efforts.
- R&D and Market Strategy: The company has resumed the pivotal Phase III HARMONY study for pegtibatinase, aiming for global patient enrollment to position the asset for late-stage development while continuing to advance FILSPARI's positioning in both IgAN and FSGS markets.
- Optimistic Financial Outlook: The CFO anticipates continued growth in FILSPARI sales for 2026, despite expectations of moderate operating expense growth and higher gross-to-net discounts, emphasizing confidence in future financial performance bolstered by ongoing market investments and product portfolio expansion.
See More
Travere Therapeutics Reports Q4 Profit Exceeding Expectations
- Earnings Beat: Travere Therapeutics reported Q4 non-GAAP earnings of $0.37 per share, significantly surpassing the expected loss of $0.04, indicating strong performance in the rare disease sector.
- Strong Sales Growth: U.S. net product sales of FILSPARI reached $103.3 million, representing a 108% increase year-over-year, contributing to total net sales rising from $73.5 million last year to $126.6 million, reflecting sustained market demand.
- Annual Performance Improvement: For the full year 2025, net product sales climbed to $410.5 million, up from $226.7 million in 2024, with FILSPARI sales totaling $322.0 million, marking a 144% year-over-year increase, showcasing the company's competitive position.
- Robust Cash Flow: At year-end, Travere had $322.8 million in cash and equivalents, providing strong financial support for ongoing commercialization and pipeline development, while also preparing for the potential launch of FILSPARI in FSGS.
See More
Travere Therapeutics Q4 Earnings Analysis
- Earnings Report: Travere Therapeutics reported a Q4 non-GAAP EPS of $0.37, aligning with market expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q4 revenue of $129.69 million, a 73.4% year-over-year increase, although it missed expectations by $17.99 million, reflecting intensified market competition and sales challenges.
- Filspari Progress: The FDA's delay in reviewing Filspari for a rare kidney disorder presents challenges, yet market expectations for its approval remain high, potentially impacting future sales growth.
- Market Outlook: Looking ahead to 2026, Travere Therapeutics anticipates that Filspari's market potential will continue to drive company growth, despite the short-term impact of the FDA review delay.
See More
Travere Therapeutics Reports Strong 2025 Financial Results and Growth Outlook
- Significant Sales Growth: In 2025, U.S. net product sales of FILSPARI reached $322 million, representing a 144% increase year-over-year, with fourth-quarter sales of $103.37 million reflecting a robust 108% growth compared to the same period in 2024, indicating strong market demand and acceptance.
- R&D Expense Reduction: Research and development expenses for Q4 2025 were $57.9 million, down from $62.1 million in Q4 2024, while total R&D expenses for the year were $206 million, showcasing the company's cost control and efficiency improvements in the development of FILSPARI and pegtibatinase.
- Net Income Turnaround: The company reported a net income of $2.7 million for Q4 2025, translating to $0.03 per share, a significant recovery from a net loss of $60.3 million in Q4 2024, demonstrating a marked improvement in financial performance and boosting investor confidence.
- Positive Future Outlook: The company anticipates receiving FDA approval for FILSPARI in FSGS by April 13, 2026, which, if granted, will open new commercial opportunities and further solidify its leadership position in the rare kidney disease market.
See More
Travere Therapeutics Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Travere Therapeutics is set to release its Q4 earnings on February 19th after market close, with a consensus EPS estimate of $0.37, reflecting a substantial year-over-year increase of 178.7%, which could boost investor confidence and potentially drive stock price appreciation.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $147.68 million, representing a 97.5% year-over-year growth, indicating robust market performance that may attract increased investor interest in the company's future prospects.
- Historical Performance Review: Over the past two years, Travere has exceeded EPS and revenue estimates 75% of the time, demonstrating financial stability that enhances market confidence in the upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates experienced three upward and three downward revisions, reflecting mixed market sentiment regarding the company's future performance, warranting close attention to the upcoming earnings release.
See More
Travere Grants Equity Inducements to New Employees
- Equity Incentive Program: On February 10, 2026, Travere Therapeutics granted 49,200 restricted stock units (RSUs) to ten new employees, highlighting the company's commitment to attracting talent and enhancing its workforce.
- Grant Conditions: These RSUs were awarded outside of the 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility in incentivizing new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only encourages long-term retention of new employees but also strengthens team stability and cohesion.
- Company Mission: Travere is dedicated to providing treatment options for rare disease patients, emphasizing its mission in the biopharmaceutical sector to improve patient lives through innovative therapies, thereby reinforcing its market position.
See More
Travere Therapeutics Q4 2025 Earnings Call Highlights
- Record Sales Performance: Travere Therapeutics achieved U.S. net product sales of $103 million for FILSPARI in Q4 2025, with total sales reaching $322 million for the year, reflecting a remarkable 144% year-over-year growth that underscores strong market demand and physician confidence, solidifying the company's leadership in IgA nephropathy treatment.
- Significant Clinical Progress: Management confirmed the acceptance of the supplemental NDA for FILSPARI in FSGS, with a revised PDUFA date of April 13, 2026, which is expected to open new market opportunities and further propel FILSPARI's clinical application and commercialization efforts.
- R&D and Market Strategy: The company has resumed the pivotal Phase III HARMONY study for pegtibatinase, aiming for global patient enrollment to position the asset for late-stage development while continuing to advance FILSPARI's positioning in both IgAN and FSGS markets.
- Optimistic Financial Outlook: The CFO anticipates continued growth in FILSPARI sales for 2026, despite expectations of moderate operating expense growth and higher gross-to-net discounts, emphasizing confidence in future financial performance bolstered by ongoing market investments and product portfolio expansion.
See More
Travere Therapeutics Reports Q4 Profit Exceeding Expectations
- Earnings Beat: Travere Therapeutics reported Q4 non-GAAP earnings of $0.37 per share, significantly surpassing the expected loss of $0.04, indicating strong performance in the rare disease sector.
- Strong Sales Growth: U.S. net product sales of FILSPARI reached $103.3 million, representing a 108% increase year-over-year, contributing to total net sales rising from $73.5 million last year to $126.6 million, reflecting sustained market demand.
- Annual Performance Improvement: For the full year 2025, net product sales climbed to $410.5 million, up from $226.7 million in 2024, with FILSPARI sales totaling $322.0 million, marking a 144% year-over-year increase, showcasing the company's competitive position.
- Robust Cash Flow: At year-end, Travere had $322.8 million in cash and equivalents, providing strong financial support for ongoing commercialization and pipeline development, while also preparing for the potential launch of FILSPARI in FSGS.
See More
Travere Therapeutics Q4 Earnings Analysis
- Earnings Report: Travere Therapeutics reported a Q4 non-GAAP EPS of $0.37, aligning with market expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved Q4 revenue of $129.69 million, a 73.4% year-over-year increase, although it missed expectations by $17.99 million, reflecting intensified market competition and sales challenges.
- Filspari Progress: The FDA's delay in reviewing Filspari for a rare kidney disorder presents challenges, yet market expectations for its approval remain high, potentially impacting future sales growth.
- Market Outlook: Looking ahead to 2026, Travere Therapeutics anticipates that Filspari's market potential will continue to drive company growth, despite the short-term impact of the FDA review delay.
See More
Travere Therapeutics Reports Strong 2025 Financial Results and Growth Outlook
- Significant Sales Growth: In 2025, U.S. net product sales of FILSPARI reached $322 million, representing a 144% increase year-over-year, with fourth-quarter sales of $103.37 million reflecting a robust 108% growth compared to the same period in 2024, indicating strong market demand and acceptance.
- R&D Expense Reduction: Research and development expenses for Q4 2025 were $57.9 million, down from $62.1 million in Q4 2024, while total R&D expenses for the year were $206 million, showcasing the company's cost control and efficiency improvements in the development of FILSPARI and pegtibatinase.
- Net Income Turnaround: The company reported a net income of $2.7 million for Q4 2025, translating to $0.03 per share, a significant recovery from a net loss of $60.3 million in Q4 2024, demonstrating a marked improvement in financial performance and boosting investor confidence.
- Positive Future Outlook: The company anticipates receiving FDA approval for FILSPARI in FSGS by April 13, 2026, which, if granted, will open new commercial opportunities and further solidify its leadership position in the rare kidney disease market.
See More
Travere Therapeutics Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Travere Therapeutics is set to release its Q4 earnings on February 19th after market close, with a consensus EPS estimate of $0.37, reflecting a substantial year-over-year increase of 178.7%, which could boost investor confidence and potentially drive stock price appreciation.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $147.68 million, representing a 97.5% year-over-year growth, indicating robust market performance that may attract increased investor interest in the company's future prospects.
- Historical Performance Review: Over the past two years, Travere has exceeded EPS and revenue estimates 75% of the time, demonstrating financial stability that enhances market confidence in the upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates experienced three upward and three downward revisions, reflecting mixed market sentiment regarding the company's future performance, warranting close attention to the upcoming earnings release.
See More
Travere Grants Equity Inducements to New Employees
- Equity Incentive Program: On February 10, 2026, Travere Therapeutics granted 49,200 restricted stock units (RSUs) to ten new employees, highlighting the company's commitment to attracting talent and enhancing its workforce.
- Grant Conditions: These RSUs were awarded outside of the 2018 Equity Incentive Plan but comply with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's flexibility in incentivizing new hires.
- Vesting Arrangement: The RSUs vest over four years with 25% vesting annually, which not only encourages long-term retention of new employees but also strengthens team stability and cohesion.
- Company Mission: Travere is dedicated to providing treatment options for rare disease patients, emphasizing its mission in the biopharmaceutical sector to improve patient lives through innovative therapies, thereby reinforcing its market position.
See More
